April 2008: Zymenex A/S, a Danish clinical-stage orphan drug development company, sold the phase II project Metazyme targeting MLD (Metachromatic Leucodystrophy) to British Shire Pharmaceuticals for USD 135 million. The transaction takes up a first place in Europe among published up-front deals in 2008.

Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69
Email Click here to contact